Slingshot members are tracking this event:

TEVA secures additional $658M in net proceeds from its equity offering via the full exercise of the underwriters over-allotment of 5.4M ADSs and 337.5K Mandatory Convertible Preferred Shares, increasing the company's take to $7.24B

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Teva intends to use the net proceeds from these offerings towards the cash portion of the purchase price for its previously announced acquisition of Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”) and related fees and expenses, for the pending acquisition of Rimsa or otherwise for general corporate purposes.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 03, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Equity Offering, Net Proceeds, Actavis Geneics Acquisition, Rimsa Acquisition